Asset profile
XmAb5871
Unknown / undisclosed
Evidence outlook · lead readout
NCT02725515 · Systemic Lupus Erythematosus
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT02725515: The study randomized 105 participants to XmAb5871 or placebo and used quadruple blinding. Its clinical primary endpoint was not met: 21 of 50 XmAb5871-treated patients versus 12 of 42 placebo-treated patients avoided loss of disease activity improvement at Day 225 (p=0.1830), despite a favorable statistically significant secondary time-to-loss result.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.